“As We have now witnessed so often times, it is usually one of the most vulnerable populations, and those who have the weakest support programs, that could be most vulnerable to the increased accessibility and usage of medications.”NIDA is conducting and supporting preclinical (laboratory) study into psilocybin’s consequences within the brain